SCHEMBL3609958

SCHEMBL3609958

CNC1CCN(CCN2c3ccccc3N(c3ccccc3)S2(O)O)CC1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 10/20 0.41
SLC6A3 Q01959 2/20 0.40
SLC6A4 P31645 2/20 0.40
CARM1 Q86X55 6/20 0.40
PRMT6 Q96LA8 6/20 0.40
KCNH2 Q12809 1/20 0.39
LTA4H P09960 1/20 0.36
SIGMAR1 Q99720 2/20 0.35
SLC18A3 Q16572 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
PRMT8 Q9NR22 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3615887 0.99 SLC6A2 (0.40) SLC6A2SLC6A3SLC6A4CARM1PRMT6
SCHEMBL3612639 0.86 SLC6A2 (0.42) SLC6A2SLC6A3SLC6A4CARM1PRMT6
SCHEMBL3609956 0.86 SLC6A2 (0.54) SLC6A2SLC6A3SLC6A4KCNH2
Hydrochloric Acid SCHEMBL3605276 0.85 SLC6A2 (0.41) SLC6A2SLC6A3SLC6A4CARM1PRMT6
Hydrochloric Acid SCHEMBL3615885 0.85 SLC6A2 (0.53) SLC6A2SLC6A3SLC6A4KCNH2
SCHEMBL3603035 0.84 SLC6A2 (0.38) SLC6A2SLC6A3SLC6A4KCNH2LTA4H
Hydrochloric Acid SCHEMBL3603335 0.83 SLC6A2 (0.38) SLC6A2SLC6A3SLC6A4KCNH2LTA4H
SCHEMBL3608801 0.80 CHRM1 (0.45) SLC6A2CARM1PRMT6KCNH2SIGMAR1
SCHEMBL3608793 0.78 SLC6A2 (0.39) SLC6A2SLC6A3SLC6A4CARM1PRMT6
Hydrochloric Acid SCHEMBL3615450 0.77 SLC6A2 (0.36) SLC6A2SLC6A3SLC6A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2010-02-04 US claimed
US-7601722-B2 Aryl sulfamide derivatives and methods of their use WYETH (US) 2009-10-13 US claimed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP claimed
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-10 US claimed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO claimed
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2010-02-04 US disclosed
US-7601722-B2 Aryl sulfamide derivatives and methods of their use WYETH (US) 2009-10-13 US disclosed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-10 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885SLC6A3 3/4885SLC6A4 1/4885
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885SLC6A3 3/4885SLC6A4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.